- Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholismAltimmune said Tuesday that its GLP-1/glucagon agonist reduced drinking in people with moderate-to-severe alcohol use disorder in a mid-stage study. Patients in the Phase 2 RECLAIM trial took a w…Endpoints · 51m ago↗ source
- Virginia federal judge says FDA should reconsider mifepristone restrictionsAt a time when the federal government is evaluating restrictions on medication abortion, a federal judge determined that the last administration imposed too many. A Virginia federal judge ordered…Endpoints · 17h ago↗ source
- The patent cliff is looming and CDMOs need to be prepared, Fujifilm CEO saysAs drugmakers prepare for the looming biopharma patent cliff, 2026 has so far been a year for dealmaking. Now, contract manufacturers need to broaden their services to keep up, Fujifilm Biotechnolo…